drugset / Trial / NCT01051388
Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation
Phase 3
Completed
280 enrolled
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Gastro-Intestinal Medical Care Research Center · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The aim of this study is to evaluate the efficacy of proton pump inhibitor (PPI), comparing to the mucosal defensive drug, in the prevention of the recurrence of gastric and/or duodenal ulcers during 12 weeks observation in patients receiving low-dose aspirin for vascular protection.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-07
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gefarnate | Small molecule | 50 mg | — |
| Comparator | Rabeprazole | Small molecule | 10 mg | — |
| Comparator | Rabeprazole | Small molecule | 20 mg | — |